Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation

NCT06385925 is registered in ClinicalTrials.gov with Tyligand Pharmaceuticals (Suzhou) Limited as lead sponsor.

NCT NCT06385925
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06385925 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation
Lead sponsor
Tyligand Pharmaceuticals (Suzhou) Limited
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 29, 2024
Completion date
April 30, 2027
Enrollment
440 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

malignant neoplasm